Clinical Account Executive

Bios Life emerges from stealth with $25M and partners with Tempus to personalize cancer screening and surveillance. BOSTON, MA, UNITED STATES, August 10, 2026 / EINPresswire.com / - Bios Life, an AI-native cancer surveillance company, today emerges from stealth with $25 million in seed financing to build a more personalized and continuous approach to cancer screening and survivorship care. The seed round was led by Redmile, Vsquared Ventures and Kindred Capital, supported by a syndicate of leading healthcare and technology investors across the United States and Europe. Bios Life is developing a personalized surveillance strategy to support high-risk individuals and cancer survivors that evolves with them over time. More than 40 million people in the US are at heightened risk for cancer or are cancer survivors, two large and underserved groups that often face fragmented and reactive care. Meanwhile more than 40% of people will be diagnosed with cancer in their lifetime, and of those more than 30% will be diagnosed at stage 3 or 4. Bios Life is creating a predictive care platform that targets these overlooked high-risk groups, bringing together advanced multi-modality foundation models and direct patient care to serve individuals across the US. At the same time the company is announcing a multi-year strategic alliance with Tempus, a leader in AI-driven precision medicine, to help train and validate its predictive models. Ryan Richardson, Co-founder and CEO, Bios Life: "Tens of millions of high-risk individuals and cancer survivors lack access to cutting-edge care which is tailored to their particular needs and their unique biology. Bios Life is building a novel technology portfolio and specialized care delivery model to uniquely serve these individuals at a level that has not been possible until now - one that is deeply personalized and delivered at scale. The support of world-class partners and investors at launch gives us the foundation to become a category-defining company in this emerging space." Bios Life aims to fundamentally redesign care for cancer survivors and those at elevated risk by delivering continuous, personalized, technology-enabled surveillance directly to patients - and in partnership with leading cancer centers - via its virtual care delivery platform with licensed care teams across the United States. Bios Life's platform launches in the US in the second half of 2026 and consumers can join the waitlist now: www.bioslife.ai. Kevin Oeffinger, MD - Director of the Duke Cancer Institute Center for Onco-Primary Care: "Cancer screening and surveillance have been at a relative standstill for the past 20-30 years. The vast majority of individuals at elevated risk of cancer are not screened according to standard-of-care guidelines, and one out of every five newly diagnosed cancers in the US is found in cancer survivors. The AI-enhanced virtual model developed by Bios Life has the potential to greatly enhance the delivery of care to these high-risk populations; this is a game changer. Utilizing AI tools with a genetic and lifestyle backbone will move us from stagnation to the long-promised potential of personalized and precise cancer screening." Personalized Care, Powered by Advanced Genomic AI Through its cutting-edge AI technology platforms and end-to-end care delivery platform, Bios Life enables the delivery of cancer surveillance and holistic supportive care tailored to each individual's unique needs. The result is a digital twin for every patient - a continuously updated model of their biology that moves away from disjointed one-time screening episodes towards integrated lifetime surveillance. At the core of Bios Life's platform is a suite of proprietary technologies, including its Personalized Cancer Risk and Cancer Surveillance Platforms. The company also holds commercial rights to the Nucleotide Transformer genomics foundation model developed by BioNTech-InstaDeep, among the most cited and most downloaded AI models for genomics worldwide, which is able to interpret genomic signals at a single-nucleotide resolution. This includes the ability to assess the impact of genetic variation across the genome, including rare and previously uncharacterized variants. Tempus Alliance Bios Life has entered a multi-year strategic alliance with Tempus, a leader in AI-driven precision medicine. The agreement allows Bios Life to leverage Tempus' de-identified multi-modal oncology datasets to train, validate, and deploy powerful predictive models across a wide range of highly prevalent cancers - moving diagnosis and surveillance from reactive scans to continuous, predictive modeling. In addition, through a collaboration with hereditary cancer testing leader Ambry Genetics, now a Tempus company, Bios Life will integrate genetic screening into its preventive platform alongside physician-ordered genetic testing within its survivorship program. Ryan Fukushima, CEO of Data and Apps, Tempus: "At Tempus, we believe the future of cancer care isn't just better treatments, it needs better prediction. Our collaboration with Bios Life is an opportunity to rethink how we identify, monitor and support individuals at elevated risk for cancer over the course of their lives. By bringing together Tempus' multi-modal data platform, Ambry's expertise in hereditary genetics, and Bios Life's virtual-first care model, we can move beyond episodic screening toward a more continuous understanding of risk. The goal is simple but ambitious: support high-risk individuals and cancer survivors with a personalized surveillance strategy that evolves with them over time." Founding Team with Deep Oncology and Health Technology Experience Bios Life is led by Co-founder & Chief Executive Officer, Ryan Richardson, the former Chief Strategy Officer of BioNTech and former Chairman of InstaDeep, BioNTech's wholly owned AI technology company. He is joined by Co-founder and Chief Operating & Business Officer, Zach Taylor, a biotech industry veteran and former Senior Vice President of BioNTech, and Co-founder and Chief Medical Officer, Logan Frank, MD, a board-certified radiologist and former Director of Breast Radiology at the University of Missouri. The management team includes technology leaders Geoff Hyde, Head of Product and Engineering, formerly a technology leader at One Medical and Galileo, and Thomas Pierrot, PhD, Head of Artificial Intelligence, who previously headed the Genomics AI research program at InstaDeep. They are supported by a nationally recognized group of advisors and leaders in cancer diagnostics, artificial intelligence, and cancer screening and survivorship. Join the waitlist for early access at www.bioslife.ai. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. 50 States Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

CellCarta adds Tempus to CDx Commercialization Lab Network. Aug 06, 2026, 09:15 ET Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model. MONTREAL, Aug. 6, 2026 /PRNewswire/ - CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM). Under the agreement, CellCarta will include Tempus in its CDx Commercialization Lab Network as the network's second commercial laboratory partner, strengthening oncology-focused companion diagnostics offerings to biopharma sponsors. Within the CellCarta network, the collaboration gives biopharma sponsors a more direct route from companion diagnostic development and regulatory approval to commercial use in U.S. oncology practice. CellCarta develops and validates the CDx, generates the analytical and clinical evidence package, supports regulatory submissions, and performs centralized immunohistochemistry (IHC) and tissue-based testing. For sponsors within the CellCarta CDx Commercialization Lab Network, Tempus will support provider test ordering through Tempus Hub, routing sample testing to CellCarta and transmitting results back to ordering healthcare providers. Tempus joins Sonic Healthcare USA as the second member of CellCarta's CDx Commercialization Lab Network, expanding the network's specialized oncology capabilities alongside Sonic's broad clinical and anatomic pathology reach across multiple disease areas. The Lab Network is part of CellCarta's CDx Accelerator Model, a flexible and modular framework organized around four stages: Build, Validate, Launch, and Transfer. Sponsors can engage CellCarta at the stage that fits their program - from assay development and validation through clinical deployment and regulatory submission. Following approval, CellCarta activates its Commercialization Lab Network partners, such as Tempus and Sonic, to support commercial launch strategies. "Tempus materially strengthens the oncology dimension of our commercialization model," said Ehab A. El-Gabry, MD, Chief Medical Officer and Head of Companion Diagnostics at CellCarta. "Sponsors can develop and validate a companion diagnostic at CellCarta, pursue a single-site approval strategy through our flexible and modular CDx Accelerator Model, and then use an established oncology diagnostics platform to support physician access and ordering. This connects regulatory execution with the realities of commercial launch." "Biopharma sponsors should not have to choose between the speed and control of a centralized CDx strategy and a credible path to physicians and patients," said Christopher Ung, Chief Scientific Business Officer of CellCarta. "Adding Tempus to our network creates a powerful route into U.S. oncology practice. It gives sponsors a practical commercialization channel from a company that oncologists already know and use, while CellCarta maintains continuity from development and regulatory approval through testing." CellCarta launched its CDx Commercialization Lab Network to address a common gap in companion diagnostic programs: securing regulatory approval does not by itself create the commercial infrastructure required for physicians to order a test and for patients to access it. The network connects CellCarta's development, regulatory, and testing capabilities with commercial laboratory partners that have established provider relationships and ordering channels. CellCarta intends to continue expanding the network by geography, therapeutic area, and commercial capability. The company's objective is to give sponsors multiple pathways for launching centralized companion diagnostics while retaining flexibility for later expansion through additional laboratories or an IVD kitted solution. To learn more about CellCarta's companion diagnostic capabilities, visit https://cellcarta.com/cdx-services/ About CellCarta CellCarta is a global CRO laboratory supporting the biopharmaceutical industry. With CAP accreditations and CLIA certifications for specific testing methods and facilities in Canada, USA, Belgium, Australia, and China, CellCarta provides biomarker testing services and customized solutions to pharmaceutical and biotechnology companies. By integrating analytical platforms in immunology, histopathology, proteomics, and genomics, along with sample management and logistics services, CellCarta supports the drug development cycle from discovery to late-stage clinical trials. Visit cellcarta.com and connect with us on LinkedIn and X. Media Contacts Stéphanie Bussières-Marmen, PhD Director, Global Marketing [email protected] Melanie Williams Senior Marketing Communications Specialist, Supreme Optimization [email protected] SOURCE CellCarta

Tempus AI has published a study in Nature Medicine showing its PRISM2 multimodal foundation model can perform diagnostic-grade cancer detection and predict biomarker status and patient prognosis. Developed with Microsoft researchers, PRISM2 outperformed or matched existing slide-level foundation models across diagnostic, biomarker, and patient outcome prediction tasks. The model was trained on 2.3 million whole-slide images and 14 million diagnostic question-answer pairs from nearly 700,000 pathology reports, making it the largest multimodal slide-level pathology dataset to date. PRISM2 combines vision models built from pathology images with large language models, turning routine hematoxylin and eosin slides into biological insights. The model can handle complex diagnostic and prognostic research tasks without specialised fine-tuning. Tempus has made the full PRISM2 model weights publicly available through Hugging Face for research and non-commercial use.